IA
IMDX

IFP Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

IFP Advisors’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,475
Closed -$98K – 4102
2022
Q4 		$98K Sell
1,475
-125
-8% -$1.38K ﹤0.01% 1749
2022
Q3 		$106K Hold
1,600
– – ﹤0.01% 1822
2022
Q2 		$106K Hold
1,600
– – ﹤0.01% 1652
2022
Q1 		$106K Buy
+1,600
New +$51.2K ﹤0.01% 1652
2020
Q3 		– Sell
-75
Closed -$2.15K – 2957
2020
Q2 		$5K Buy
+75
New +$3.87K ﹤0.01% 2098
2017
Q4 		– Hold
0
– – – 4016
2017
Q3 		– Hold
0
– – – 4162
2017
Q2 		– Hold
0
– – – 4169
2017
Q1 		– Hold
0
– – – 4083
2016
Q4 		– Hold
0
– – – 4083
2016
Q3 		– Hold
0
– – – 3991
2016
Q2 		– Hold
0
– – – 3996

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

IFP Advisors's IMDX Position: Q1 2023 in Review

IFP Advisors sold out of Insight Molecular Diagnostics (IMDX) in Q1 2023, closing a stake of 1,475 shares — an estimated $98K sold.

IFP Advisors first reported a position in IMDX in Q2 2020 and held it in 5 quarters. The position peaked at $106K in Q3 2022. 52 funds tracked by Wall St. Rank hold IMDX as of Q1 2023.

  • IFP Advisors reported no remaining Insight Molecular Diagnostics position as of Q1 2023 after selling out during the quarter.
  • IFP Advisors sold 1,475 Insight Molecular Diagnostics shares in Q1 2023, an estimated $98K.
  • IFP Advisors first reported a position in Insight Molecular Diagnostics in Q2 2020 and held it in 5 quarters.
  • IFP Advisors's Insight Molecular Diagnostics position peaked at $106K in Q3 2022.
  • 52 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2023.

Based on IFP Advisors's 13F filing for Q1 2023, filed 18 Apr 2023.